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Alzheimer’s disease (AD), a progressive neurodegenerative disease, is characterized
by the accumulation of senile plaques, neurofibrillary tangles, and loss of synapses
and neurons in the brain. The pathophysiological process of AD begins with a long
asymptomatic phase, which provides a potential opportunity for early therapeutic
intervention. Therefore, it is crucial to define putative biomarkers via reliable and validated
methods for early diagnosis of AD. Here, we characterized candidate biomarkers by
discovery proteomics analysis of cerebrospinal fluid (CSF), revealing that 732 and
704 proteins with more than one unique peptide were identified in healthy controls
and preclinical AD patients, respectively. Among them, 79 and 98 proteins were
significantly altered in preclinical AD for women and men, respectively, many of which
have been demonstrated with consistent regulation pattern in patients with mild
cognitive impairment or AD dementia. In-house developed 5-plex isotopic N,N-dimethyl
leucine (iDiLeu) tags were further utilized to verify candidate biomarkers, neurosecretory
protein VGF (VGF) and apolipoprotein E (apoE). By labeling peptide standards with
different iDiLeu tags, a four-point internal calibration curve was constructed to allow for
determination of the absolute amount of target analytes in CSF through a single liquid
chromatography-mass spectrometry run.
Keywords: cerebrospinal fluid, Alzheimer’s disease, biomarker, label-free quantitation, targeted quantitative
proteomics, isotopic labeling for quantitation, iDiLeu
INTRODUCTION
Alzheimer’s disease (AD) is the most common form of dementia among the elderly. It is
characterized by deposition of peptide amyloid-β (Aβ) as amyloid plaques and of protein tau as
neurofibrillary tangles (Blennow et al., 2006). Complemented with molecular imaging techniques,
cerebrospinal fluid (CSF) markers have been established to reflect AD pathologies (Blennow
et al., 2010; Zetterberg, 2015). Emerging clinical cohort studies suggest that subtle cognitive
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alteration begins years before mild cognitive impairment
(Sperling et al., 2011). It is crucial to establish a panel of
reliable protein biomarkers for diagnosis of AD at very earliest
stage (Hampel et al., 2010). CSF Aβ42 is a well-established
marker of Aβ plaque pathology that is highly predictive of
AD in cognitively normal individuals (Dubois et al., 2016).
Although several peptide and protein biomarkers in CSF have
been used for aiding in AD diagnosis (Puchades et al., 2003;
Hall et al., 2012), an unambiguous diagnosis of AD at preclinical
stage is still lacking. To establish novel and reliable biomarkers
capable of early diagnosis in preclinical AD, mass spectrometry
(MS) is implemented for unbiased candidate protein biomarker
discovery as the principal enabling technology. MS-based
label-free quantification holds special promise to discover
significant disease-related protein dysregulations for large
cohorts with high throughput and sensitivity. The potential
biomarkers can be further verified through targeted proteomics
with high accuracy and reproducibility (Peterson et al., 2012).
Enzyme-linked immunosorbent assay (ELISA) is widely used
for biomarker verification in clinical laboratories, but the
dependence on high-quality antibodies restrict its feasibility to
quantify novel protein biomarkers (Hüttenhain et al., 2009).
Absolute quantification (AQUA) strategy was first proposed to
use known concentrations of synthesized heavy isotope-encoded
peptides as internal standards to quantify concentrations of
native peptides in the clinical sample (Gerber et al., 2003).
However, the number of biomarker candidates to be verified
would be limited due to the high cost of AQUA. Alternatively,
mass difference labeling strategies such as stable isotope labeling
by amino acids in cell culture (SILAC) (Ong et al., 2002;
Seyfried et al., 2010), combined precursor isotopic labeling and
isobaric tagging (cPILOT) (Robinson and Evans, 2012), amino
acid-coded tagging (Pan et al., 2003), and mass differential
tags for relative and absolute quantification (mTRAQ) (Kang
et al., 2010) introduce heavy isotopes metabolically or chemically
into target peptides to yield different precursor ion masses,
which can be quantified through full MS scans. For example,
mTRAQ can react with free N-terminus of a peptide through
N-hydroxysuccinimide (NHS) ester group, there is no need to
preselect target peptide to incorporate stable isotopes (Ross et al.,
2004). mTRAQ is a relatively cost-efficient approach compared to
AQUA, but like AQUA (Pannee et al., 2013), the three channels
used for mTRAQ limit its ability to construct a standard curve
with at most two channels to label standards and the third to label
sample, leading to inaccurate estimates when protein amounts
span a wide dynamic range in CSF.
The development of a set of five mass-difference reagents,
isotopic N,N-dimethyl leucine (iDiLeu) tags, offers greatly
reduced cost and significantly improves quantification
throughput as compared to AQUA and mTRAQ (Greer
et al., 2015). iDiLeu labeling strategy enables construction of a
four-point calibration curve to quantify analytes in a single liquid
chromatography–mass spectrometry (LC–MS) run. Each of the
5-plex iDiLeu reagents is comprised of an isotopic N,N-dimethyl
leucine and an amine-reactive triazine ester moiety, which
selectively labels the N-terminus of peptides as well as lysine
side chains (Supplementary Figure S1). Mass additions of
141.1154, 144.1313, 147.1409, 150.1631, and 153.1644 Da are
efficiently incorporated into peptides by d0, d3, d6, d9, and
d12 labels, respectively. Different mass shifts can be discrete in
the MS1 precursor ion scan for quantification, while tandem
mass (MS2) yields abundant sequence-specific fragment ions
for identification. Four iDiLeu labels are used to set up internal
calibration curve by labeling peptide standards with known
concentrations and the fifth channel is used to label target
peptide of interest in CSF, making absolute quantification
achievable based on the intensity of precursor ions in one
LC–MS run. Here, we report a comparative global proteomics
study in CSF from healthy and preclinical AD individuals to
discover candidate biomarkers, which are further validated by
targeted quantitative analysis with 5-plex iDiLeu tagging strategy
(Figure 1).
FIGURE 1 | Workflow for label-free quantification-based discovery proteomics and isotopic labeling-based targeted proteomics.
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MATERIALS AND METHODS
Participants
Twelve enrollees (six individuals in preclinical AD stage and
equal number of healthy controls) from Wisconsin Alzheimer’s
Disease Research Center (ADRC) participated in this study.
The participants comprised of three women in preclinical
AD and three gender, family history, and years of education
matched healthy controls respectively, as well as three paired
men. Table 1 summarizes the demographic characteristics of
the participants. Classification of participants as cognitively
normal was based on a comprehensive neuropsychological test
battery (Almeida et al., 2015). Global cognitive function was
evaluated by Mini-Mental State Examination (MMSE), on which
a score of ≤24 is deemed an indication of cognition impairment
(Folstein et al., 1975). All participants had MMSE scores of ≥28,
indicating cognition normal. Classification of preclinical AD was
based on evidence of amyloid beta (Aβ) accumulation on 11C
Pittsburgh Compound B Positron emission tomography (PET)
imaging and hypometabolism on 18F Fluoro-2-deoxy-glucose
(FDG)-PET. The University of Wisconsin Institutional Review
Board approved all study procedures. All participants provided
signed informed consent.
CSF Protein Digestion
One mL CSF samples were collected through lumbar puncture.
After 3 kDa molecular weight cut off separation, the concentrated
protein was subjected to Sigma LC2 IgY column and 14 most
abundant proteins were depleted to reduce sample complexity.
95–99% depletion efficiency was achieved and the unbound
protein was measured by 660 nm protein assay kit (Thermo
Scientific Pierce) at absorbance of 660 nm in Tecan Ultra
384 multi-detection microplate reader (Männedorf, Switzerland).
Equal amounts of CSF proteins were reduced by adding
dithiothreitol to a final concentration of 5 mM and incubated
at room temperature for 1 h. 15 mM of iodoacetamide was
used for alkylation of cysteines by incubating for 30 min
at room temperature in the dark. After quenching unreacted
iodoacetamide with 5 mM dithiothreitol, the protein mixture
was diluted with 50 mM Tris buffer (pH 8) to a final urea
concentration of 1 M prior to digestion with trypsin at a
protein:enzyme ratio of 50:1 at 37◦C for 16 h. The digestion
reaction was quenched by acidification with 10% trifluoroacetic
acid (TFA) to pH 3, followed by desalting with Bond Elut
OMIX C18 pipette tips (Agilent Technologies, Santa Clara, CA,
United States). For targeted proteomics, another one mL CSF
samples were dried down in vacuum via centrifugation with
a SpeedVac concentrator (Thermo Scientific, Waltham, MA,
United States) and resuspended in 100 µL of lysis buffer, which
contained 8 M urea, 50 mM tris base (adjust pH to 8 with
hydrochloric acid), 5 mM CaCl2, 20 mM NaCl, and 1 tablet
of EDTA-free protease inhibitor cocktail. CSF proteins were
quantified and digested as above.
Synthesis and Activation of iDiLeu
Reagents
Synthesis of 5-plex iDiLeu isobaric tags was previously described
in detail (Xiang et al., 2010; Greer et al., 2015). iDiLeu tags
stored at −20◦C are very stable until activation for labeling. The
activation buffer consisted of 4-(4,6-dimethoxy-1,3,5-triazin-
2-yl)-4-methylmorpholinium tetrafluoroborate (DMTMM) and
N-methylmorpholine (NMM) at 0.6x molar ratios of iDiLeu
tags dissolved in anhydrous N,N-dimethylformamide (DMF).
Activation of iDiLeu tags was conducted by vortexing at room
temperature for 1 h. The mixture was centrifuged at 14,000 × g
for 1 min and the supernatant was transferred immediately for
peptide labeling.
Peptides Labeling by 5-Plex iDiLeu Tags
A stock solution of synthesized neurosecretory VGF peptide
(THLGEALAPLSK) was prepared to be 1 µg/µL. Five aliquots
were set up for labeling with d0, d3, d6, d9, d12 iDiLeu reagent,
respectively. In each aliquot, 20 µg of peptide standards were
resuspended in 20 µL of 0.5 M triethylammonium bicarbonate
(TEAB) buffer. To ensure sufficient labeling, peptide standards
ware labeled with a 20x w/w excess of iDiLeu reagents. 60 µL
of activated iDiLeu reagents were added to each peptide
standards aliquot to make the organic:aqueous ratio of 75%.
The reaction was vortexing for 2 h under room temperature.
50% hydroxylamine was added to final 0.25% to quench the
reaction and incubated for another 10 min. Labeled peptides were
vacuum-dried. Two hundred µg of apoE protein standard was
digested based on the digestion procedure described above. Each
of five aliquots containing 20 µg of apoE protein standard digests
was labeled with the five-channel iDiLeu reagents individually.
For correction factor, 2.5 µg of peptide standards were
reconstituted in strong cation exchange (SCX) reconstitution
buffer. By-products of iDiLeu labeling reaction were removed
TABLE 1 | Characteristics of the current study participants.
Diagnosis Gender Age (years) Education (years) MMSE score Amyloid∗ (11C
PiB-PET)
Glucose∗
(FDG-PET)
Family history of
dementia (n)
ApoE ε4
carriers (n)
Control n = 3 W 54.4 ± 3.8 15.3 ± 0.9 29.3 ± 0.5 −0.7 ± 0.3 0.5 ± 0.2 2 0
Predinical AD n = 3 W 58.4 ± 3.5 17.3 ± 1.2 29.0 ± 0.8 1.0 ± 11.3 −0.9 ± 0.5 3 3
Control n = 3 M 62.3 ± 2.5 15.3 ± 2.5 30.0 ± 0 −0.6 ± 0.3 1.2 ± 0.5 2 1
Predinical AD n = 3 M 63.8 ± 2.0 17.0 ± 0.8 29.7 ± 0.5 1.5 ± 1.6 −1.1 ± 0.8 2 1
Data are presented as mean ± standard deviation. AD, Alzheimer’s disease; W, women; M, men; MMSE, Mini-Mental State Examination; 11C-PiB, 11C-labeled Pittsburgh
compound B; PET, Positron emission tomography; FDG, 18F-fluorodeoxyglucose. ∗These measures are in arbitrary units (a.u.). The amyloid burden data (PiB-PET) were
residualized for the effects of age and gender. The glucose metabolism data (FDG-PET) were residualized for the effects of age, gender, and global glucose metabolism.
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from SCX SpinTips (Protea Biosciences, Morgantown, WV,
United States) according to the manufacturer’s protocol. The
eluate was dried in vacuo and desalted with ZipTip C18 pipette
tips (Merck Millipore, Darmstadt, Germany).
Cerebrospinal fluid protein digests were reconstituted in
20 µL of 0.5 M TEAB and labeled with d0 reagent separately
according to the peptide standards labeling procedure described
above. The other four channels labeled peptide standards were
spiked into each d0-labeled CSF sample in a ratio of 1:10:50:100.
The combined sample was cleaned up with SCX SpinTips and
desalted with Bond Elut OMIX C18 pipette tips. All the labeled
samples were then dried in vacuo and reconstituted in 25 µL of
3% acetonitrile (ACN), 0.1% formic acid (FA) in water.
LC–MS/MS Acquisition
Samples were analyzed using a Waters nanoAcquity
ultra-performance liquid chromatography (UPLC) system
(Milford, MA, United States) coupled to a Thermo Scientific
Q-Exactive Orbitrap mass spectrometer (San Jose, CA,
United States). Peptide mixture was loaded onto a fabricated
column with an integrated emitter tip, which packed with
Bridged Ethylene Hybrid C18 particles (75 µm × 150 mm,
1.7 µm, 130 Å). Mobile phase A was 0.1% FA in H2O and mobile
phase B was 0.1% FA in ACN. Peptides were separated with
a gradient elution of 4 to 35% B over 90 min at a flow rate of
300 nL/min. Full MS scan was acquired in profile mode ranging
from m/z 350 to 1800 at a resolution of 70 K. Automatic gain
control (AGC) target was 1 × 106, and maximum injection time
was 120 ms. Tandem mass spectra were acquired at centroid
mode. The top 15 most abundant precursor ions were selected
for higher-energy collisional dissociation (HCD) fragmentation
with a dynamic exclusion for 40 s with a 10 ppm tolerance.
Data-dependent acquisition parameters were set as resolution
power of 17.5 K, isolation window of 2.0 Th, normalized collision
energy (NCE) of 27, the maximum injection time of 150 ms,
AGC target of 1 × 105, and fixed first mass of m/z 110. For
targeted proteomics, an inclusion list containing all the precursor
ions of peptide of interest was constructed. Each sample was
acquired in technical triplicates.
Data Analysis
In discovery proteomics analysis, protein identification was
performed using MaxQuant (1.5.6.5) against SwissProt human
database with 1% false discovery rate (FDR) at protein level.
The first search peptide tolerance for precursor and product
ion were 20 ppm and 0.02 Da, respectively. The maximum
missed cleavages per peptide was 2. Fixed modification was set
as carbamidomethylation of cysteine residues (+57.0215 Da).
Oxidation of methionine (+15.9949 Da) was selected as
variable modifications. The intensity obtained from label-free
quantification in MaxQuant was uploaded into Perseus for
advanced downstream analysis. Firstly, the reverse protein
sequences created during database search, the most common
contaminants in the MS analyses, and proteins identified
only by modified sequences were removed. Secondly, proteins
identified based on only one peptide and proteins for which no
unique peptide was identified were removed. To ensure accurate
quantification, proteins identified in each sample along three
technical replicates were normalized to the summed intensity,
followed by determination of the ratio between preclinical AD
FIGURE 2 | Venn diagram illustration of proteins identified in healthy controls (gray) and preclinical AD patients (orange) for women (A) and men (B), respectively.
Volcano plots of quantified proteins in women (C) and men (D).
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FIGURE 3 | GO analysis of significantly regulated proteins in women (A) and men (B) with preclinical AD. GO term with Fisher Exact p-value smaller than 0.05 was
considered to be a strongly enriched biological process.
and healthy control as well as statistical analysis of Student’s
t-test. Gene ontology (GO) analysis of the significantly regulated
proteins in preclinical AD patients was performed by DAVID,
which is a tool to provide enrichment analysis of the most
relevant GO terms associated with a given list (Huang et al.,
2009).
In targeted proteomics analysis, protein identification was
performed on Peaks Studio 7 software (Bioinformatics Solutions,
Inc., Waterloo, ON, Canada). The data refinement was applied to
correct precursor mass by default. All the raw files were searched
against UniProt Homo sapiens reviewed database with trypsin as
digestion enzyme. The error tolerance for precursor mass was
25 ppm using monoisotopic mass and 0.02 Da for fragment ion.
The maximum missed cleavages per peptide was two, allowed to
be cleaved at both ends of the peptides. Fixed modification was
set as carbamidomethylation of cysteine residues (+57.0215 Da).
iDiLeu labels (+141.1154 Da for d0, +144.1313 Da for d3,
+147.1409 Da for d6, +150.1631 Da for d9, and +153.1644 Da
for d12) of peptide N-termini and lysine residues, as well as
oxidation of methionine (+15.9949 Da) were selected as variable
modifications. Estimation of FDR was enabled. Peptides with
FDR < 1% were considered to be unambiguous identification.
Peak areas generated by Genesis peak detection algorithm in
Thermo Xcalibur 2.2 software were used for quantification. The
precursor ion integration tolerance was 15 ppm. Retention time
of extracted ion chromatogram of 5-plex iDiLeu-labeled peptides
was required to be within 2 min. Isotopic interference correction
factors were applied to each sample to rectify the raw values.
RESULTS AND DISCUSSION
Label-Free Quantification for Discovery
Proteomics
To discover candidate protein biomarkers for early diagnosis of
AD in preclinical stage, label-free based discovery proteomics
displayed in Figure 1 was employed for measurement of protein
changes between healthy and preclinical AD individuals as a
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FIGURE 4 | Calibration curves of 5-plex iDiLeu labeled VGF peptide in triplicates. The normalized peak area of precursor ions plotted as a function of peptide
concentrations at 0.3–30, 3–300, 30–3000 fmol/µL.
faster and cleaner technique. Given sex differences in the risk
of AD (Mielke et al., 2014), the study was designed so that
gender could be taken into account in all the analyses. As shown
in Figure 2A, 708 and 690 proteins were identified in healthy
and preclinical AD for women with 1% protein-level FDR,
respectively. The identified proteins in men were comparable to
women (659 and 653 proteins in each group, Figure 2B). Taken
collectively, 732 and 704 proteins with more than one unique
peptide were identified in healthy controls and preclinical AD
patients.
All the identified proteins were submitted to Perseus for
advanced downstream analysis (Tyanova et al., 2016). To
ensure accurate quantification, proteins identified based on
only one peptide were removed. Proteins identified in sex-
matched three pairs of healthy and preclinical AD subjects
along with all the technical replicates were utilized for label-
free quantification. As shown in volcano plots (Figures 2C,D),
79 and 98 proteins were significantly altered in preclinical
AD for women and men in comparison to corresponding
healthy controls, respectively (Supplementary Tables S1A,B).
They were sequentially used for gene ontology (GO) enrichment
analysis to understand what biological processes were statistically
over-represented. The top 10 biological processes with Fisher
FIGURE 5 | Example of tandem mass spectrum for iDiLeu d0-labeled apoE
peptide in CSF.
Exact p-value < 0.05 in preclinical AD for women and men
were shown in Figure 3. Negative regulation of endopeptidase
activity, platelet degranulation, and cell adhesion were the three
most prominent biological processes in both women and men,
all of which were related to AD pathology. Many endopeptidases
are capable of proteolyzing Aβ, especially neprilysin, which
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FIGURE 6 | Calibration curves of proteins VGF and apoE constructed in both healthy (A,B) and preclinical AD (C,D) subjects.
exhibits the most potent Aβ-degrading activity (Shirotani et al.,
2001). Down-regulated neprilysin in the hippocampus and
cerebral cortex has been reported in AD development (Shirotani
et al., 2001). Platelet degranulation played an important role in
platelet-mediated amyloid beta (Aβ) oligomerization (Donner
et al., 2016). It was suggested that Aβ stimulated aberrant
neuritic growth by activation of cell adhesion signaling pathways
(Cotman et al., 1998; Grace et al., 2002).
Many of the differentially expressed proteins have been
demonstrated to have similar up- or down-regulation patterns
in earlier studies of MCI or AD dementia, including elevated
amyloid beta precursor protein in women with preclinical
AD (p-value = 0.006), which could be further proteolytically
cleaved into neurotoxic Aβ42 peptide (Zlokovic, 2005; Sleegers
et al., 2006). Secretogranin II, a precursor for neuropeptide
secretoneurin, widely distributed in endocrine and nervous
tissues, was decreased (p-value = 0.00003) in men with preclinical
AD as compared to healthy subjects (Li et al., 2008). Interestingly,
some proteins displayed opposite regulation trends between
women and men in preclinical AD. Neurosecretory protein VGF
(VGF), synthesized by neurons where it promotes dendritic
growth and survival of cortical neurons (Sato et al., 2012),
was significantly down-regulated in men with preclinical AD
but increased in women. Apolipoprotein E (apoE) has three
common isoforms, all of which differentially modulate Aβ
aggregation and clearance (Bu, 2009). ApoE was up-regulated
in women with preclinical AD patients but slightly decreased
in men. Biomarker candidates of VGF and apoE determined
from discovery proteomics need to be further validated through
isotopic labeling-based targeted proteomics.
Quantitative Performance of 5-Plex
iDiLeu Labeling Strategy
To demonstrate the strong performance of 5-plex iDiLeu
labeling strategy, a mixture of 5-plex iDiLeu-labeled
peptide standards were employed for characterization and
quantification. The starting material, L-leucine or isotopic
L-leucine (L-leucine-1-13C, 15N) used for iDiLeu synthesis
are commercially available, but the slight impurities of these
reagents can diminish quantification accuracy. Furthermore,
when 5-plex iDiLeu reagents only label the N-terminus of a
peptide with +2 charge state, the m/z of five monoisotopic
precursors will be 1.5 Th apart, which will inevitably introduce
isotopic interference. Therefore, correction factors need to be
firstly determined for each of the 5-plex iDiLeu tags to ensure
accurate quantification (Supplementary Table S2). A series of
equations based on i-Tracker were set up to rectify raw values
with correction factors (Shadforth et al., 2005; Greer et al.,
2015). Each channel has its own correction equation, where
the peak area of both monoisotopic precursor and any possible
interferences from neighboring isotopic precursor were taken
into consideration.
Peptide standards were labeled with 5-plex iDiLeu reagents.
The combination of 5-plex iDiLeu labeled peptides was subjected
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to LC–MS/MS analysis in triplicates at the ratio of 1:1:1:1:1.
Extracted ion chromatograms of precursor ions were used for
quantification of 5-plex iDiLeu-labeled peptides. The median
ratio of d0:d3:d6:d9:d12 was 0.89:1.08:0.87:0.85:1.00 as shown
in the boxplots (Supplementary Figure S2). Medians displayed
high accuracy with <15% error, which confirms quantification
based on MS1-precursor level was reliable in high-resolution and
accurate mass (HRAM) measurement by Q-Exactive Orbitrap
mass spectrometer.
To determine the linear concentration range of this iDiLeu
labeling strategy, standards of VGF peptide and tryptic apoE
peptides were individually labeled with 5-plex iDiLeu tags and
combined at the ratio of 1:10:50:100. The highest concentration
stock of VGF peptide ranged from 30 to 3000 fmol/µL. This
stock solution was serially diluted twice to prepare concentrations
of 3–300 and 0.3–30 fmol/µL. Figure 4 displayed peak
area of iDiLeu-labeled VGF peptide at the MS1 level as a function
of concentration across LC–MS/MS analysis in triplicates by
normalization to d9 channel. Each calibration curve revealed
a linear response comprising R2 around 0.999 spanning two
orders of magnitude. The higher the concentration, the lower
the coefficient of variation (CV). The CV was below 0.8% in the
concentration of 30–3000 fmol/µL but increased to be 8% among
the triplicates in 0.3–30 fmol/µL. The limits of quantification
for VGF peptide and tryptic apoE peptides were all around
0.1 fmol/µL. The high linearity and low limit of quantification
confirmed that iDiLeu tagging is a robust strategy for absolute
quantification.
Absolute Quantification of Biomarkers in
Preclinical Alzheimer’s Disease
The iDiLeu labeling strategy has been evaluated with high
accuracy and linearity, allowing for verification of biomarker
candidates in CSF samples. We set up the targeted proteomics
strategy to perform quantification in both healthy and preclinical
AD subjects using 5-plex iDiLeu reagents (Figure 1). Each CSF
protein digests was labeled with d0 channel, respectively. Peptide
standards were composed of peptides derived from proteins VGF
and apoE. The standards were labeled with d3, d6, d9, d12,
individually, followed by combination at the ratio of 1:10:50:100.
The four channels labeled peptide standards were spiked into
each CSF sample with equal amount at the same ratio. The
final concentration of peptide standard was ranged from 0.04 to
4 pmol/µL for proteins VGF and apoE.
iDiLeu labeled peptides were fragmented under NCE of
27. Figure 5 displayed representative tandem mass spectrum
of d0-labeled peptide AATVGSLAGQPLQER in CSF sample.
iDiLeu d0 tag was fragmented to produce dimethylated
immonium reporter ion at m/z of 114.1. Abundant b- and y-
product ions have been matched to specific peptide sequence
within an FDR < 1%, which is equivalent to a −10lgP score
of 15. This score is derived from the p-value that indicates the
statistical significance of the peptide-spectrum match (Zhang
et al., 2012). Peptide AATVGSLAGQPLQER of apoE had−10lgP
score of 58.13, which presented as a high-quality spectrum with
modification of iDiLeu tag. The plot of normalized peak area
FIGURE 7 | The determination of absolute amounts of proteins VGF and apoE
in CSF of women (A,B) and men (C,D).
of each peptide against concentration displayed high linearity
in both preclinical AD and control samples, which ensured the
accuracy of biomarker quantification (Figure 6). A standard
deviation within 3% was demonstrated across the triplicates run
in each sample.
The amounts of VGF were quantified as 55 and 21 ng/mL in
CSF of women and men with preclinical AD, respectively. ApoE
has higher abundance than VGF, which were 1.38 and 0.9 µg/mL
in preclinical AD for women and men, respectively (Figure 7).
The isotopic labeling based targeted proteomics suggested that
both VGF and apoE were down-regulated in men with preclinical
AD but showing opposite regulation pattern in women, which
is consistent with that of label-free based discovery proteomics.
The average ages for women were younger than men, which may
partially contribute to the opposite phenomenon as aging is the
greatest risk factor for AD. Moreover, women had significantly
higher glucose metabolism in the brain areas involved in the
pathological process of AD, while men showed consistent level
of cognitive impairment (Perneczky et al., 2007). Sex difference
in cortical cytoarchitecture, such as brain size, neuron account,
and neuron density, may also lead to brain cognitive reserve
difference in women and men (Rabinowicz et al., 2002).
There is no clear consensus regarding whether VGF and
apoE are positively or negatively associated with AD dementia
(Hesse et al., 2000; Carrette et al., 2003; Liu et al., 2013;
Busse et al., 2015; Hölttä et al., 2015). Statistical analysis
demonstrated that VGF was significantly down-regulated in men
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with preclinical AD, possibly due to its regulation of
hippocampal function and memory, in part through modulation
of brain-derived neurotrophic factor (BDNF) secretion and
signaling (Bozdagi et al., 2008). The increased expression of VGF
in women may be correlated to immune manifestations with
negative effects on brain function and neuronal repair processes,
as reported that VGF was expressed with a higher percentage
of peripheral CD3+ T cells from AD patients compared to
age-matched healthy controls (Akiyama et al., 2000; Busse et al.,
2015).
ApoE is a lipoprotein containing 299 amino acids, regulates
lipid homeostasis by mediating lipid transport between various
cells in the brain. The delivering function of Aβ peptide is
thought to initiate toxic events, leading to synaptic dysfunction
and neurodegeneration in AD (Liu et al., 2013). Analysis of apoE
alleles in AD demonstrated that there was a significant association
of ε4 allele with an earlier age of AD onset, resulting from domain
interactions in the presence of arginine at residue 112 (Kim et al.,
2009; Wolf et al., 2013). ApoE may function as Aβ chaperones
for receptor-mediated clearance of soluble extracellular Aβ but
may also lead to intraneuronal Aβ accumulation (Lane and
Farlow, 2005). The absolute amount and particular isoform of
apoE may influence both Aβ fibrillogenesis and metabolism to
differing extents. It has been reported that increased cytokines
and decreased cholesterol in the brain could reduce apoE levels
in AD (Gueguen et al., 2001). However, higher levels of apoE
have also been reported in CSF of AD patients compared with
age-matched controls (Lindh et al., 1997; Sihlbom et al., 2008).
According to our results, 1.38 and 0.9 µg/mL of apoE could
be defined as thresholds for women and men with preclinical
AD, respectively, but a large cohort study would be necessary to
determine the threshold of multiple biomarkers to aid pre-clinical
diagnosis.
CONCLUSION
In summary, we reported a large number of proteins identified
in human CSF. A panel of potential protein biomarkers
was produced to differentiate healthy controls and preclinical
AD patients in this pilot study. Many of the candidate
biomarkers have shown similar trends in patients with MCI
or AD, including amyloid precursor protein, apolipoprotein E,
and several neuroendocrine proteins. More interestingly, the
differential expression of proteins in women and men with
preclinical AD might provide us with a novel perspective to reveal
the pathological mechanism of AD, but a larger cohort study is
necessary to further elucidate the correlation between AD and
gender differences. For the first time, the novel iDiLeu-enabled
standard curve approach has been established for absolute
quantification of candidate protein biomarkers in each CSF
sample with high accuracy and reproducibility. Taken together,
we established a comprehensive strategy to discover and verify
candidate biomarkers by integrating label-free based discovery
proteomics with isotopic labeling based targeted proteomics. This
strategy could be applied for biomarker discovery and verification
across a broad spectrum of diseases.
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